Abstract:BackgroundHigh tumor mutational burden (TMB) is an emerging biomarker of sensitivity to immune checkpoint inhibitors and has been shown to be more significantly associated with response to PD-1 and PD-L1 blockade immunotherapy than PD-1 or PD-L1 expression, as measured by immunohistochemistry (IHC). The distribution of TMB and the subset of patients with high TMB has not been well characterized in the majority of cancer types.MethodsIn this study, we compare TMB measured by a targeted comprehensive genomic profiling (CGP) assay to TMB measured by exome sequencing and simulate the expected variance in TMB when sequencing less than the whole exome. We then describe the distribution of TMB across a diverse cohort of 100,000 cancer cases and test for association between somatic alterations and TMB in over 100 tumor types.ResultsWe demonstrate that measurements of TMB from comprehensive genomic profiling are strongly reflective of measurements from whole exome sequencing and model that below 0.5 Mb the variance in measurement increases significantly. We find that a subset of patients exhibits high TMB across almost all types of cancer, including many rare tumor types, and characterize the relationship between high TMB and microsatellite instability status. We find that TMB increases significantly with age, showing a 2.4-fold difference between age 10 and age 90 years. Finally, we investigate the molecular basis of TMB and identify genes and mutations associated with TMB level. We identify a cluster of somatic mutations in the promoter of the gene PMS2, which occur in 10% of skin cancers and are highly associated with increased TMB.ConclusionsThese results show that a CGP assay targeting ~1.1 Mb of coding genome can accurately assess TMB compared with sequencing the whole exome. Using this method, we find that many disease types have a substantial portion of patients with high TMB who might benefit from immunotherapy. Finally, we identify novel, recurrent promoter mutations in PMS2, which may be another example of regulatory mutations contributing to tumorigenesis.

High burden and pervasive positive selection of somatic mutations in normal human skin

UV-exposure, endogenous DNA damage, and DNA replication errors shape the spectra of genome changes in human skin

Pervasive Induction of Regulatory Mutation Microclones in Sun-exposed Skin

Spatial constraints govern competition of mutant clones in human epidermis

A body map of somatic mutagenesis in morphologically normal human tissues

Skin cancer risk is increased by somatic mutations detected noninvasively in healthy-appearing sun-exposed skin

Whole-genome landscapes of major melanoma subtypes

Whole genome DNA sequencing provides an atlas of somatic mutagenesis in healthy human cells and identifies a tumor-prone cell type

Somatic mutation and selection at epidemiological scale

Genetic evolution of keratinocytes to cutaneous squamous cell carcinoma

Driver gene combinations dictate cutaneous squamous cell carcinoma disease continuum progression

A multi-phenotype analysis reveals 19 susceptibility loci for basal cell carcinoma and 15 for squamous cell carcinoma

Mutational Processes Molding the Genomes of 21 Breast Cancers

Genomic and transcriptomic analysis of cutaneous squamous cell carcinoma arising in immunocompetent and immunosuppressed patients

Negative selection allows human primary fibroblasts to tolerate high somatic mutation loads induced by N-ethyl-N-nitrosourea

Extensive heterogeneity in somatic mutation and selection in the human bladder

The somatic mutation landscape of normal gastric epithelium

Signatures of mutational processes in human cancer

Transposon mutagenesis identifies cooperating genetic drivers during keratinocyte transformation and cutaneous squamous cell carcinoma progression

Somatic Point Mutation Calling in Low Cellularity Tumors

Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden